Alector因中期无效性分析决定终止Nivisnebart(AL101/GSK4527226)治疗早期阿尔茨海默病的二期PROGRESS-AD试验

美股速递
Apr 30

生物制药公司Alector Inc.宣布,将停止其候选药物Nivisnebart(研发代号AL101/GSK4527226)用于治疗早期阿尔茨海默病的二期PROGRESS-AD临床试验。此项决定是基于一项预先计划的中期分析结果,该分析显示试验未能达到预期的疗效终点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10